Cosmo Pharmaceuticals N.V. (ETR:C43)

Cosmo Pharmaceuticals Statistics

Total Valuation

ETR:C43 has a market cap or net worth of EUR 826.85 million. The enterprise value is 692.61 million.

Market Cap	826.85M
Enterprise Value	692.61M

Important Dates

The last earnings date was Wednesday, July 23, 2025.

Earnings Date	Jul 23, 2025
Ex-Dividend Date	Jun 4, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.94%
Shares Change (QoQ)	+3.31%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	8.52M

Valuation Ratios

The trailing PE ratio is 6.21.

PE Ratio	6.21
Forward PE	n/a
PS Ratio	3.10
PB Ratio	1.64
P/TBV Ratio	2.64
P/FCF Ratio	5.24
P/OCF Ratio	5.09
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.29, with an EV/FCF ratio of 4.39.

EV / Earnings	5.20
EV / Sales	2.59
EV / EBITDA	4.29
EV / EBIT	4.64
EV / FCF	4.39

Financial Position

The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.00.

Current Ratio	4.19
Quick Ratio	3.39
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	2,809.09

Financial Efficiency

Return on equity (ROE) is 29.31% and return on invested capital (ROIC) is 20.39%.

Return on Equity (ROE)	29.31%
Return on Assets (ROA)	15.87%
Return on Invested Capital (ROIC)	20.39%
Return on Capital Employed (ROCE)	24.88%
Revenue Per Employee	828,534
Profits Per Employee	413,776
Employee Count	322
Asset Turnover	0.45
Inventory Turnover	3.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.25% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.25%
50-Day Moving Average	60.89
200-Day Moving Average	70.81
Relative Strength Index (RSI)	34.20
Average Volume (20 Days)	65

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ETR:C43 had revenue of EUR 266.79 million and earned 133.24 million in profits. Earnings per share was 8.12.

Revenue	266.79M
Gross Profit	221.43M
Operating Income	148.88M
Pretax Income	153.37M
Net Income	133.24M
EBITDA	160.47M
EBIT	148.88M
Earnings Per Share (EPS)	8.12

Balance Sheet

The company has 142.96 million in cash and 2.20 million in debt, giving a net cash position of 140.76 million.

Cash & Cash Equivalents	142.96M
Total Debt	2.20M
Net Cash	140.76M
Net Cash Per Share	n/a
Equity (Book Value)	505.09M
Book Value Per Share	31.12
Working Capital	153.99M

Cash Flow

In the last 12 months, operating cash flow was 162.41 million and capital expenditures -4.55 million, giving a free cash flow of 157.86 million.

Operating Cash Flow	162.41M
Capital Expenditures	-4.55M
Free Cash Flow	157.86M
FCF Per Share	n/a

Margins

Gross margin is 83.00%, with operating and profit margins of 55.81% and 49.94%.

Gross Margin	83.00%
Operating Margin	55.81%
Pretax Margin	57.49%
Profit Margin	49.94%
EBITDA Margin	60.15%
EBIT Margin	55.81%
FCF Margin	59.17%

Dividends & Yields

This stock pays an annual dividend of 2.05, which amounts to a dividend yield of 3.94%.

Dividend Per Share	2.05
Dividend Yield	3.94%
Dividend Growth (YoY)	2.50%
Years of Dividend Growth	2
Payout Ratio	24.09%
Buyback Yield	-1.94%
Shareholder Yield	2.00%
Earnings Yield	16.11%
FCF Yield	19.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ETR:C43 has an Altman Z-Score of 7.21.

Altman Z-Score	7.21
Piotroski F-Score	n/a